Oral gallium maltolate trial for recurrent glioblastoma

The National Institutes of Health registered ClinicalTrials.gov study NCT07515924, a Phase 1 interventional trial evaluating oral gallium maltolate in patients with recurrent glioblastoma. The trial will assess safety, tolerability, and maximum tolerated dose in an estimated patient cohort. Gallium maltolate is an investigational gallium-based compound under study for potential anticancer activity against glioblastoma.

BAT5906 Biosimilar vs Lucentis for Diabetic Macular Edema

Bio-Thera Solutions registered a Phase 3 clinical trial (NCT07515079) on ClinicalTrials.gov evaluating BAT5906, a biosimilar candidate referencing Lucentis (ranibizumab), for treating diabetic macular edema. The randomized, double-blind study will compare the efficacy and safety of BAT5906 injection versus reference Lucentis in patients with diabetic macular edema. Trial enrollment is ongoing.

NX-5948 versus pirtobrutinib relapsed refractory CLL SLL trial

ClinicalTrials.gov registered a new Phase 3 randomized trial (NCT07516093) comparing NX-5948 to pirtobrutinib in adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The single-arm study will evaluate efficacy and safety endpoints.

AstraZeneca studies nurandociguat drug interactions with rosuvastatin, dabigatran

AstraZeneca registered a Phase I clinical trial on ClinicalTrials.gov investigating potential drug interactions between nurandociguat and two established medications—rosuvastatin (a statin) and dabigatran (an anticoagulant). The single-arm study will evaluate pharmacokinetic parameters in healthy participants to assess how co-administration affects drug exposure and safety profiles.

Boehringer Ingelheim Vicadrostat Cardiac Study Registration

Boehringer Ingelheim registered a clinical trial (NCT07513207) on ClinicalTrials.gov investigating vicadrostat for cardiac applications. The study is now publicly visible in the federal clinical trial registry. Trial sponsors must register applicable clinical trials under FDA requirements.

AbbVie ABBV-295 phase 1 trial, Japanese adults, obesity

AbbVie ABBV-295 phase 1 trial, Japanese adults, obesity

Sintilimab bevacizumab gastric cancer trial Zhongshan Hospital

National Library of Medicine registered a new clinical trial (NCT07515625) on ClinicalTrials.gov evaluating sintilimab combined with bevacizumab for treating advanced gastric or gastroesophageal junction adenocarcinoma at Zhongshan Hospital in China. The single-arm Phase 2 study will enroll approximately 20 participants.

Clinical trial NCT07515456, theophylline vs sumatriptan, gabapentin

NIH National Library of Medicine registered clinical trial NCT07515456 on ClinicalTrials.gov. The trial is a Phase 2/3 randomized study evaluating theophylline compared to sumatriptan and gabapentin for an undisclosed condition, enrolling approximately 60 participants aged 18-65.

FinCEN Healthcare Fraud Advisory - 24 Red Flags and Enhanced Reporting

FinCEN issued an advisory on March 30, 2026, urging financial institutions to be vigilant in identifying and reporting suspicious transactions related to healthcare fraud schemes targeting Medicare, Medicaid, and other federal and state health care benefit programs. The advisory applies broadly to banks, broker-dealers, investment companies, insurance companies, and certain real estate businesses, providing 24 red flag indicators for identifying fraud and money laundering activity. Financial institutions are encouraged to voluntarily report suspicious activity and notify law enforcement regarding fraud schemes targeting Health Care Benefit Programs.

Flipky trademark TM76392800 registered, semiconductor devices

USPTO registered the FLIPKY trademark (TM76392800) for semiconductor devices on April 2, 2026, with a filing date of April 8, 2002. The registration establishes intellectual property protection for the FLIPKY mark in Class 009 covering semiconductor devices.